Geoff Meacham
Stock Analyst at Citigroup
(3.85)
# 748
Out of 4,667 analysts
218
Total ratings
52.48%
Success rate
8.27%
Average return
Main Sectors:
Stocks Rated by Geoff Meacham
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GILD Gilead Sciences | Initiates: Buy | $125 | $88.99 | +40.47% | 6 | Nov 14, 2024 | |
| REGN Regeneron Pharmaceuticals | Initiates: Neutral | $895 | $746.92 | +19.83% | 18 | Nov 14, 2024 | |
| BIIB Biogen | Initiates: Neutral | $190 | $157.30 | +20.79% | 12 | Nov 14, 2024 | |
| VRTX Vertex Pharmaceuticals | Initiates: Buy | $575 | $447.50 | +28.49% | 4 | Nov 14, 2024 | |
| AMGN Amgen | Initiates: Neutral | $335 | $288.96 | +15.94% | 10 | Nov 14, 2024 | |
| ABBV AbbVie | Maintains: Buy | $226 → $215 | $170.67 | +25.97% | 14 | Nov 12, 2024 | |
| LLY Eli Lilly | Maintains: Buy | $1,150 → $1,100 | $743.41 | +47.97% | 9 | Oct 31, 2024 | |
| LYEL Lyell Immunopharma | Downgrades: Underperform | $6 → $1 | $0.95 | +4.92% | 3 | Oct 30, 2024 | |
| TYRA Tyra Biosciences | Upgrades: Buy | $22 → $31 | $15.91 | +94.85% | 2 | Oct 18, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $130 → $115 | $62.28 | +84.65% | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $130 → $110 | $36.80 | +198.91% | 9 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 | $23.34 | +79.99% | 4 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $10 | $0.45 | +2,098.29% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $150 → $145 | $98.29 | +47.52% | 6 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $45 | $43.41 | +3.66% | 2 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $80 | $44.43 | +80.06% | 1 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $180 → $170 | $154.55 | +10.00% | 3 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $38 | $26.56 | +43.10% | 2 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $7 | $0.57 | +1,132.39% | 4 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $48 | $48.00 | - | 2 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $45 → $30 | $43.78 | -31.48% | 3 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $68 → $60 | $57.98 | +3.48% | 8 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 | $9.00 | -11.06% | 2 | Dec 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $9.79 | +83.86% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $23 → $14 | $6.65 | +110.68% | 2 | Sep 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $10 → $8 | $2.50 | +220.64% | 4 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $17 | $2.03 | +739.51% | 1 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $14 | $2.32 | +504.75% | 3 | Jul 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $50 → $45 | $24.93 | +80.51% | 6 | Apr 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $5.18 | +865.25% | 1 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $24 | $4.16 | +476.88% | 4 | Nov 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $4 | $6.40 | -37.50% | 2 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $37 → $34 | $20.93 | +62.49% | 2 | Dec 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $2.55 | +1,000.20% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $1.22 | +2,686.89% | 1 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $56 | $10.16 | +451.45% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $35 | $2.46 | +1,325.66% | 4 | Jan 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $525 | $5.84 | +8,883.73% | 1 | Nov 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $42 | $1.62 | +2,492.59% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $110 | $46.15 | +138.35% | 1 | Oct 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $20 | $5.88 | +240.14% | 1 | Sep 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $20 | $1.95 | +925.64% | 2 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $2.70 | +640.74% | 1 | Aug 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underperform | $9 | $2.92 | +208.22% | 1 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $60 | $9.22 | +550.76% | 1 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $7 | $4.31 | +62.41% | 1 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $23 | $13.81 | +66.55% | 3 | Aug 5, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $90 → $82 | $70.25 | +16.73% | 9 | May 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $100 → $95 | $365.80 | -74.03% | 6 | Mar 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $60 → $16 | $0.49 | +3,140.18% | 3 | Dec 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $43 → $40 | $42.36 | -5.57% | 7 | Nov 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $135 | $124.08 | +8.81% | 2 | Aug 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $14.33 | - | 4 | May 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $20 | $3.44 | +481.40% | 4 | May 3, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | n/a | $45.56 | - | 2 | Apr 5, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $127 → $158 | $249.58 | -36.69% | 5 | Nov 8, 2017 |
Gilead Sciences
Nov 14, 2024
Initiates: Buy
Price Target: $125
Current: $88.99
Upside: +40.47%
Regeneron Pharmaceuticals
Nov 14, 2024
Initiates: Neutral
Price Target: $895
Current: $746.92
Upside: +19.83%
Biogen
Nov 14, 2024
Initiates: Neutral
Price Target: $190
Current: $157.30
Upside: +20.79%
Vertex Pharmaceuticals
Nov 14, 2024
Initiates: Buy
Price Target: $575
Current: $447.50
Upside: +28.49%
Amgen
Nov 14, 2024
Initiates: Neutral
Price Target: $335
Current: $288.96
Upside: +15.94%
AbbVie
Nov 12, 2024
Maintains: Buy
Price Target: $226 → $215
Current: $170.67
Upside: +25.97%
Eli Lilly
Oct 31, 2024
Maintains: Buy
Price Target: $1,150 → $1,100
Current: $743.41
Upside: +47.97%
Lyell Immunopharma
Oct 30, 2024
Downgrades: Underperform
Price Target: $6 → $1
Current: $0.95
Upside: +4.92%
Tyra Biosciences
Oct 18, 2024
Upgrades: Buy
Price Target: $22 → $31
Current: $15.91
Upside: +94.85%
BioMarin Pharmaceutical
Sep 17, 2024
Maintains: Buy
Price Target: $130 → $115
Current: $62.28
Upside: +84.65%
Sep 13, 2024
Maintains: Neutral
Price Target: $130 → $110
Current: $36.80
Upside: +198.91%
Sep 11, 2024
Maintains: Buy
Price Target: $42
Current: $23.34
Upside: +79.99%
Aug 19, 2024
Maintains: Buy
Price Target: $12 → $10
Current: $0.45
Upside: +2,098.29%
Jul 31, 2024
Maintains: Buy
Price Target: $150 → $145
Current: $98.29
Upside: +47.52%
Jun 13, 2024
Maintains: Buy
Price Target: $40 → $45
Current: $43.41
Upside: +3.66%
May 10, 2024
Initiates: Buy
Price Target: $80
Current: $44.43
Upside: +80.06%
Apr 17, 2024
Maintains: Neutral
Price Target: $180 → $170
Current: $154.55
Upside: +10.00%
Apr 12, 2024
Maintains: Buy
Price Target: $40 → $38
Current: $26.56
Upside: +43.10%
Mar 13, 2024
Maintains: Buy
Price Target: $8 → $7
Current: $0.57
Upside: +1,132.39%
Mar 13, 2024
Maintains: Buy
Price Target: $24 → $48
Current: $48.00
Upside: -
Jan 3, 2024
Downgrades: Neutral
Price Target: $45 → $30
Current: $43.78
Upside: -31.48%
Jan 3, 2024
Downgrades: Neutral
Price Target: $68 → $60
Current: $57.98
Upside: +3.48%
Dec 15, 2023
Downgrades: Neutral
Price Target: $8
Current: $9.00
Upside: -11.06%
Oct 10, 2023
Initiates: Buy
Price Target: $18
Current: $9.79
Upside: +83.86%
Sep 8, 2023
Downgrades: Neutral
Price Target: $23 → $14
Current: $6.65
Upside: +110.68%
Aug 21, 2023
Maintains: Underperform
Price Target: $10 → $8
Current: $2.50
Upside: +220.64%
Aug 21, 2023
Maintains: Buy
Price Target: $19 → $17
Current: $2.03
Upside: +739.51%
Jul 20, 2023
Reinstates: Buy
Price Target: $14
Current: $2.32
Upside: +504.75%
Apr 21, 2023
Maintains: Neutral
Price Target: $50 → $45
Current: $24.93
Upside: +80.51%
Jan 5, 2023
Initiates: Buy
Price Target: $50
Current: $5.18
Upside: +865.25%
Nov 1, 2022
Downgrades: Underperform
Price Target: $24
Current: $4.16
Upside: +476.88%
Jun 8, 2022
Downgrades: Neutral
Price Target: $12 → $4
Current: $6.40
Upside: -37.50%
Dec 29, 2021
Maintains: Buy
Price Target: $37 → $34
Current: $20.93
Upside: +62.49%
Aug 10, 2021
Initiates: Buy
Price Target: $28
Current: $2.55
Upside: +1,000.20%
Jul 13, 2021
Initiates: Buy
Price Target: $34
Current: $1.22
Upside: +2,686.89%
May 7, 2021
Upgrades: Buy
Price Target: $56
Current: $10.16
Upside: +451.45%
Jan 15, 2021
Downgrades: Neutral
Price Target: $35
Current: $2.46
Upside: +1,325.66%
Nov 23, 2020
Initiates: Buy
Price Target: $525
Current: $5.84
Upside: +8,883.73%
Oct 20, 2020
Initiates: Buy
Price Target: $42
Current: $1.62
Upside: +2,492.59%
Oct 5, 2020
Initiates: Buy
Price Target: $110
Current: $46.15
Upside: +138.35%
Sep 15, 2020
Reinstates: Buy
Price Target: $20
Current: $5.88
Upside: +240.14%
Sep 8, 2020
Reinstates: Buy
Price Target: $20
Current: $1.95
Upside: +925.64%
Aug 4, 2020
Initiates: Buy
Price Target: $20
Current: $2.70
Upside: +640.74%
Jun 25, 2020
Reinstates: Underperform
Price Target: $9
Current: $2.92
Upside: +208.22%
Jun 25, 2020
Reinstates: Buy
Price Target: $60
Current: $9.22
Upside: +550.76%
Jun 25, 2020
Initiates: Underperform
Price Target: $7
Current: $4.31
Upside: +62.41%
Aug 5, 2019
Maintains: Equal-Weight
Price Target: $15 → $23
Current: $13.81
Upside: +66.55%
May 3, 2019
Downgrades: Equal-Weight
Price Target: $90 → $82
Current: $70.25
Upside: +16.73%
Mar 1, 2019
Maintains: Underweight
Price Target: $100 → $95
Current: $365.80
Upside: -74.03%
Dec 20, 2018
Downgrades: Equal-Weight
Price Target: $60 → $16
Current: $0.49
Upside: +3,140.18%
Nov 6, 2018
Maintains: Equal-Weight
Price Target: $43 → $40
Current: $42.36
Upside: -5.57%
Aug 1, 2018
Maintains: Overweight
Price Target: $100 → $135
Current: $124.08
Upside: +8.81%
May 21, 2018
Downgrades: Underweight
Price Target: n/a
Current: $14.33
Upside: -
May 3, 2018
Maintains: Equal-Weight
Price Target: $16 → $20
Current: $3.44
Upside: +481.40%
Apr 5, 2018
Downgrades: Equal-Weight
Price Target: n/a
Current: $45.56
Upside: -
Nov 8, 2017
Maintains: Overweight
Price Target: $127 → $158
Current: $249.58
Upside: -36.69%